{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0"},{"groupId":"OG001","value":"7.6"},{"groupId":"OG002","value":"11.8"}]}],"title":"Diarrhea, Baseline (n=173,170,153)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7"},{"groupId":"OG001","value":"17.9"},{"groupId":"OG002","value":"34.7"}]}],"title":"Diarrhea, Cycle 1 Day 8 (n=124,117,98)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2"},{"groupId":"OG001","value":"11.3"},{"groupId":"OG002","value":"39.6"}]}],"title":"Diarrhea, Cycle 2 Day 1 (n=161,160,144)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4"},{"groupId":"OG001","value":"8.1"},{"groupId":"OG002","value":"41.1"}]}],"title":"Diarrhea, Cycle 2 Day 8 (n=125,123,107)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"171"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"The FACT-C is a self-reported instrument which measures HRQOL pertaining to colorectal cancer. Response options on each question may range from 0 (not at all) to 4 (very much). The percentage of participants with diarrhea was calculated using following formula: \\[number of participants with any level of either symptom divided by the number analyzed\\] multiplied by 100.","groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"OG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"paramType":"NUMBER","populationDescription":"ITT Population (Protocol Amendment C Subpopulation). Only participants with a FACT-C score at the designated visit (n) were included in the analysis.","reportingStatus":"POSTED","timeFrame":"At Baseline, Day 8 of Cycle 1, and Days 1 and 8 of Cycle 2","title":"Percentage of Participants Reporting Diarrhea According to the Relevant Single Items of The FACT-C Module","type":"SECONDARY","unitOfMeasure":"percentage of participants"}